Chemotherapeutic induction of cytosolic single-stranded DNA accumulation sensitizes triple-negative breast cancer to immunotherapy.

Yong Du¹, Li Yang², Hui Dai³, Jianli Zhou⁴, Zhicheng Zhou⁵, Ruoxi Yuan⁶, Rui Ye³, Anh Thai Quynh Nguyen³, Kishor Bhatia⁴, Shiaw-Yih Lin¹

¹Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA sylin@mdanderson.org duyongfnp@gmail.com.

²Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.

³Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

⁴Lantern Pharma Inc, Dallas, Texas, USA.

⁵The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

⁶Hospital for Special Surgery, New York, New York, USA.

PubMed PMC DOI PDF

Abstract

BACKGROUND: Despite the widespread adoption of chemoimmunotherapy in triple-negative breast cancer (TNBC), the mechanisms by which cytotoxic chemotherapy engages antitumor immunity remain poorly defined. Identifying tumor-intrinsic immunogenic programs that predict and enhance responsiveness to immune checkpoint blockade (ICB) is therefore of critical clinical importance. METHODS: Transcriptomic…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.